petition from t315i patients on the web, page-12

What is the existing number of patients with t315i mutations today? Can anyone source this independantly of company estimates?

Because, if there are only 300 patients and the drug sells for $100K pa, that is only $30m per year. then subtract COGS, sales team, operating expenses, tax...wont be much profit left! so market valuation of company of $100m today would seem expensive.

However, if there is an exisiting pool of patients (I'm sure there is but can t find any info on this) then maybe I'd believe the stock is undervalued.

any help would be greatly appreciated.